TCRX - TScan Therapeutics, Inc.
IEX Last Trade
3.02
-0.005 -0.166%
Share volume: 12,905
Last Updated: Fri 27 Dec 2024 08:30:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$3.02
0.00
-0.17%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-10 | 2022-11-09 | 2023-03-08 | 2023-05-10 | 2023-08-10 | 2023-11-09 | 2024-03-06 | 2024-05-13 | |
| Assets | |||||||||
| Total Assets | 152.415 M | 165.454 M | 199.091 M | 173.577 M | 316.923 M | 291.379 M | 272.149 M | 240.832 M | |
| Current Assets | 129.360 M | 141.177 M | 124.127 M | 100.907 M | 242.218 M | 217.567 M | 194.237 M | 164.721 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.757 M | 3.871 M | 4.100 M | 5.299 M | 1.450 M | 2.144 M | 2.193 M | 1.938 M | |
| Short Term Investments | 3.757 M | 3.871 M | 4.100 M | 5.299 M | 1.450 M | 2.144 M | 2.193 M | 1.938 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 31.926 M | 0.000 | 0.000 | 0.000 | |
| Current Cash | 125.603 M | 137.306 M | 120.027 M | 95.608 M | 208.842 M | 215.423 M | 192.044 M | 162.783 M | |
| Total Non-current Assets | 23.055 M | 24.277 M | 74.964 M | 72.670 M | 74.705 M | 73.812 M | 77.912 M | 76.111 M | |
| Property Plant Equipment | 10.803 M | 10.334 M | 10.100 M | 9.019 M | 8.206 M | 8.595 M | 7.742 M | 7.201 M | |
| Other Assets | 7.215 M | 8.906 M | 59.827 M | 58.620 M | 61.468 M | 60.186 M | 65.139 M | 63.879 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 152.415 M | 165.454 M | 199.091 M | 173.577 M | 316.923 M | 291.379 M | 272.149 M | 240.832 M | |
| Total liabilities | 20.763 M | 48.796 M | 99.657 M | 95.559 M | 126.316 M | 122.418 M | 121.282 M | 117.865 M | |
| Total current liabilities | 17.170 M | 16.594 M | 17.305 M | 14.047 M | 35.118 M | 33.151 M | 29.820 M | 31.479 M | |
| Accounts Payable | 3.096 M | 2.708 M | 2.912 M | 2.773 M | 3.394 M | 3.196 M | 2.374 M | 2.123 M | |
| Other liabilities | 97.000 K | 97.000 K | 49.000 K | 36.000 K | 7.668 M | 7.770 M | 5.622 M | 4.758 M | |
| Current long term debt | 1.746 M | 1.795 M | 3.681 M | 3.836 M | 4.209 M | 5.486 M | 6.593 M | 10.135 M | |
| Long term debt | 3.496 M | 32.105 M | 82.303 M | 81.476 M | 83.530 M | 81.497 M | 85.840 M | 81.628 M | |
| Other liabilities | 97.000 K | 97.000 K | 49.000 K | 36.000 K | 7.668 M | 7.770 M | 5.622 M | 4.758 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 131.652 M | 116.658 M | 99.434 M | 78.018 M | 190.607 M | 168.961 M | 150.867 M | 122.967 M | |
| Common stock | 24.064 M | 24.074 M | 24.081 M | 24.226 M | 47.209 M | 94.830 M | 96.135 M | 94.876 M | |
| Retained earnings | -123.411 M | -139.656 M | -158.379 M | -180.942 M | -204.987 M | -227.984 M | -247.597 M | -277.739 M |